Captrust Financial Advisors Immuno Gen, Inc. Transaction History

Captrust Financial Advisors

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $355,122 - $853,604	-28,501 Reduced 29.57%	67,877 $2.01 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $493,304 - $695,668	35,011 Added 57.05%	96,378 $1.53 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $129,307 - $691,364	34,482 Added 128.26%	61,367 $1.16 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $1,552 - $2,081	-423 Reduced 1.55%	26,885 $103,000
Q4 2022 Feb 15, 2023	BUY	$4.55 - $6.31 $124,251 - $172,313	27,308 New	27,308 $135,000
Q2 2022 Aug 23, 2022	SELL	$3.15 - $5.76 $3,150 - $5,760	-1,000 Reduced 33.16%	2,016 $9,000
Q2 2022 Aug 16, 2022	BUY	$3.15 - $5.76 $3,150 - $5,760	1,000 Added 49.6%	3,016 $14,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $703 - $1,110	148 Added 7.92%	2,016 $15,000
Q3 2021 Nov 16, 2021	BUY	$5.02 - $6.59 $5,632 - $7,393	1,122 Added 150.4%	1,868 $11,000
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $3,237 - $5,243	498 Added 200.81%	746 $6,000
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $1,110 - $2,298	-300 Reduced 54.74%	248 $2,000
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $1,819 - $2,926	548 New	548 $3,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $1,008 - $2,598	-448 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$1.8 - $3.3 $194 - $356	108 Added 31.76%	448 $1,000
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $819 - $2,009	340 New	340 $1,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $448 - $867	-67 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $339 - $530	67	67 $0

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.